{"id":"nabpaclitaxel","rwe":[{"pmid":"41899178","year":"2026","title":"Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41896491","year":"2026","title":"Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.","finding":"","journal":"Journal of cancer research and clinical oncology","studyType":"Clinical Study"},{"pmid":"41892321","year":"2026","title":"Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.","finding":"","journal":"Cells","studyType":"Clinical Study"},{"pmid":"41883967","year":"2026","title":"Case Report: Management challenges of active tuberculosis complicated by thrombocytosis and squamous cell lung carcinoma.","finding":"","journal":"Frontiers in oncology","studyType":"Clinical Study"},{"pmid":"41883866","year":"2026","title":"Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.","finding":"","journal":"Therapeutic advances in medical oncology","studyType":"Clinical Study"}],"tags":[{"label":"Microtubule Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Tubulin beta-3 chain","category":"target"},{"label":"TUBB3","category":"gene"},{"label":"TUBB","category":"gene"},{"label":"TUBB1","category":"gene"},{"label":"L01CD01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Carcinoma of breast","category":"indication"},{"label":"Carcinoma of fallopian tube","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Kaposi's sarcoma","category":"indication"},{"label":"Malignant tumor of cervix","category":"indication"},{"label":"Malignant tumor of ovary","category":"indication"},{"label":"Hq Spclt Pharma","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Antimitotic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Phytogenic","category":"pharmacology"},{"label":"Tubulin Modulators","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":3162.161,"date":"","count":2867,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 2,867 times (LLR=3162)"},{"llr":3136.121,"date":"","count":4038,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 4,038 times (LLR=3136)"},{"llr":2796.109,"date":"","count":2893,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 2,893 times (LLR=2796)"},{"llr":2243.822,"date":"","count":2858,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 2,858 times (LLR=2244)"},{"llr":2063.329,"date":"","count":2847,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 2,847 times (LLR=2063)"},{"llr":1518.387,"date":"","count":3685,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 3,685 times (LLR=1518)"},{"llr":1474.021,"date":"","count":1058,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 1,058 times (LLR=1474)"},{"llr":1378.114,"date":"","count":944,"signal":"Metastases to liver","source":"DrugCentral FAERS","actionTaken":"Reported 944 times (LLR=1378)"},{"llr":1210.745,"date":"","count":831,"signal":"Metastases to bone","source":"DrugCentral FAERS","actionTaken":"Reported 831 times (LLR=1211)"},{"llr":1180.668,"date":"","count":1363,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 1,363 times (LLR=1181)"},{"llr":1122.342,"date":"","count":1336,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 1,336 times (LLR=1122)"},{"llr":1051.615,"date":"","count":2095,"signal":"Erythema","source":"DrugCentral FAERS","actionTaken":"Reported 2,095 times (LLR=1052)"},{"llr":1017.279,"date":"","count":2329,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 2,329 times (LLR=1017)"},{"llr":1010.634,"date":"","count":1480,"signal":"Leukopenia","source":"DrugCentral FAERS","actionTaken":"Reported 1,480 times (LLR=1011)"},{"llr":950.14,"date":"","count":557,"signal":"Peripheral sensory neuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 557 times (LLR=950)"}],"commonSideEffects":[{"effect":"Bone Marrow Neutropenia <2,000/mm3","drugRate":"92%","severity":"serious"},{"effect":"Bone Marrow Neutropenia <500/mm3","drugRate":"81%","severity":"serious"},{"effect":"Thrombocytopenia <100,000/mm3","drugRate":"30%","severity":"serious"},{"effect":"Thrombocytopenia <50,000/mm3","drugRate":"10%","severity":"serious"},{"effect":"Anemia <11 g/dL","drugRate":"86%","severity":"serious"},{"effect":"Anemia <8 g/dL","drugRate":"13%","severity":"serious"},{"effect":"Infections","drugRate":"25%","severity":"serious"},{"effect":"Hypersensitivity Reaction","drugRate":"12%","severity":"serious"},{"effect":"Peripheral Neuropathy","drugRate":"60%","severity":"common"},{"effect":"Myalgia/Arthralgia","drugRate":"60%","severity":"common"},{"effect":"Nausea and Vomiting","drugRate":"56%","severity":"common"},{"effect":"Mucositis","drugRate":"52%","severity":"common"},{"effect":"Alopecia","drugRate":"96%","severity":"common"},{"effect":"Neurotoxicity","drugRate":"20%","severity":"common"}],"contraindications":["Acute cerebrovascular insufficiency","Acute exacerbation of asthma","Acute infectious disease","Acute nephropathy","Anaphylaxis","Anemia","Asthma","Bone marrow depression","Bradycardia","Breastfeeding (mother)","Bronchospasm","Cardiogenic shock","Chronic heart failure","Complete atrioventricular block","Conduction disorder of the heart","Decompensated cardiac failure","Depressive disorder","Diabetes mellitus","Disease of liver","Heart block","Hyperbilirubinemia","Hypoglycemic disorder","Kidney disease","Liver function tests abnormal","Low blood pressure"],"specialPopulations":{"Lactation":"There are no data on the presence of paclitaxel in human milk, or its effect on the breastfed child or on milk production. In animal studies, paclitaxel and/or its metabolites were excreted into the milk of lactating rats. Because of the potential for serious adverse reactions in breastfed child from paclitaxel protein-bound particles for injectable suspension (albumin-bound), advise lactating women not to breastfeed during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound).","Pregnancy":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm when administered to pregnant woman. Advise females of reproductive potential of the potential risk to fetus. The background rate of major birth defects and miscarriage is unknown for the indicated population. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pregnancy Category D.","Geriatric use":"Of 2,228 patients who received paclitaxel in clinical studies evaluating its safety and effectiveness in the treatment of advanced ovarian cancer, breast carcinoma, or NSCLC, and 1,570 patients who were randomized to receive paclitaxel in the adjuvant breast cancer study, 649 patients (17%) were 65 years or older and 49 patients (1%) were 75 years or older. In most studies, severe myelosuppression was more frequent in elderly patients; in some studies, severe neuropathy was more ","Paediatric use":"The safety and effectiveness of paclitaxel in pediatric patients have not been established. There have been reports of central nervous system (CNS) toxicity (rarely associated with death) in clinical trial in pediatric patients in which paclitaxel was infused intravenously over hours at doses ranging from 350 mg/m2 to 420 mg/m2."}},"trials":[],"aliases":["Abraxane","Abraxane®"],"company":"Pfizer","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2034-07-12","territory":"US","patentNumber":"9511046*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2034-01-12","territory":"US","patentNumber":"9511046"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"9393318*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"9597409*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-03-04","territory":"US","patentNumber":"9393318"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-03-04","territory":"US","patentNumber":"9597409"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-02-13","territory":"US","patentNumber":"8034375*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-21","territory":"US","patentNumber":"7758891*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-21","territory":"US","patentNumber":"8268348*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-21","territory":"US","patentNumber":"9101543*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-13","territory":"US","patentNumber":"8034375"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-21","territory":"US","patentNumber":"7758891"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-21","territory":"US","patentNumber":"8268348"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-21","territory":"US","patentNumber":"9101543"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-04-27","territory":"US","patentNumber":"7820788*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-10-27","territory":"US","patentNumber":"7820788"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-06-09","territory":"US","patentNumber":"7923536*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-06-09","territory":"US","patentNumber":"8138229*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-06-09","territory":"US","patentNumber":"8314156*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-09","territory":"US","patentNumber":"7923536"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-09","territory":"US","patentNumber":"8138229"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-09","territory":"US","patentNumber":"8314156"}],"pricing":[],"allNames":"taxol","offLabel":[],"synonyms":["paclitaxel","(-)-Paclitaxel","abraxane","capxol","cyclopax","ebetaxel","genaxol","mitotax","padexol","plaxicel","taxol","Taxol A","Tocosol Paclitaxel","nabpaclitaxel","ABI-007","nab-paclitaxel"],"timeline":[{"date":"1992-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hq Spclt Pharma)"},{"date":"2019-05-10","type":"positive","source":"DrugCentral","milestone":"EMA approval (Teva Bv)"},{"date":"2019-09-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Taiho Pharmaceutical Co., Ltd.)"}],"aiSummary":"Taxol, also known as paclitaxel, is being studied in combination with low-dose radiotherapy and pucotenlimab for the treatment of advanced pancreatic cancer. It is also being investigated in combination with the AG regimen for this condition, as well as in other studies involving PD-L1 and PD-1 inhibitors.","brandName":"Taxol","ecosystem":[{"indication":"Carcinoma of breast","otherDrugs":[{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"epirubicin","slug":"epirubicin","company":"Pfizer Inc"}],"globalPrevalence":160000000},{"indication":"Carcinoma of fallopian tube","otherDrugs":[],"globalPrevalence":null},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Kaposi's sarcoma","otherDrugs":[{"name":"daunorubicin","slug":"daunorubicin","company":""},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"vinblastine","slug":"vinblastine","company":""}],"globalPrevalence":null},{"indication":"Malignant tumor of cervix","otherDrugs":[{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"cemiplimab","slug":"cemiplimab","company":"Regeneron Pharmaceuticals "},{"name":"topotecan","slug":"topotecan","company":"Novartis Pharms Corp"}],"globalPrevalence":null},{"indication":"Malignant tumor of ovary","otherDrugs":[{"name":"altretamine","slug":"altretamine","company":"Eisai Inc"},{"name":"carboplatin","slug":"carboplatin","company":""},{"name":"cisplatin","slug":"cisplatin","company":"Hq Spclt Pharma"},{"name":"doxorubicin","slug":"doxorubicin","company":""}],"globalPrevalence":null},{"indication":"Malignant tumor of peritoneum","otherDrugs":[{"name":"bevacizumab","slug":"bevacizumab","company":"Genentech"},{"name":"niraparib","slug":"niraparib","company":"Tesaro Inc"},{"name":"olaparib","slug":"olaparib","company":"Astrazeneca Pharms"}],"globalPrevalence":null},{"indication":"Metastatic Breast Carcinoma","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"eribulin","slug":"eribulin","company":"Eisai Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Tubulin beta-3 chain","novelty":"Follow-on","targets":[{"gene":"TUBB3","source":"DrugCentral","target":"Tubulin beta-3 chain","protein":"Tubulin beta-3 chain"},{"gene":"TUBB","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta chain"},{"gene":"TUBB1","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-1 chain"},{"gene":"TUBB2A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2A chain"},{"gene":"TUBB2B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2B chain"},{"gene":"TUBB4A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4A chain"},{"gene":"TUBB4B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4B chain"},{"gene":"TUBB6","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-6 chain"},{"gene":"TUBB8","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-8 chain"},{"gene":"OPRD1","source":"DrugCentral","target":"Delta-type opioid receptor","protein":"Delta-type opioid receptor"}],"modality":"Small Molecule","drugClass":"Microtubule Inhibitor","explanation":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.","oneSentence":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division.","technicalDetail":"Taxol binds to the beta subunit of tubulin, stabilizing microtubules and preventing their dynamic instability, which is essential for cell division. This results in cell cycle arrest at the G2/M phase, leading to apoptosis in cancer cells."},"commercial":{"launchDate":"1992","revenueYear":2025,"_launchSource":"DrugCentral (FDA 1992-12-29, HQ SPCLT PHARMA)","annualRevenue":368,"revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:02.206315","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2044","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Nabpaclitaxel","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nabpaclitaxel","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:44:42.895516","biosimilars":[],"competitors":[{"drugName":"docetaxel","drugSlug":"docetaxel","fdaApproval":"1996-05-14","patentExpiry":"Sep 30, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cabazitaxel","drugSlug":"cabazitaxel","fdaApproval":"2010-06-17","patentExpiry":"Oct 27, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"nabpaclitaxel","indications":{"approved":[{"name":"Carcinoma of breast","source":"DrugCentral","snomedId":254838004,"regulator":"FDA","eligibility":{"adjuvant therapy":"node-positive breast cancer, administered sequentially to standard doxorubicin-containing combination chemotherapy","first-line therapy":"node-positive breast cancer, administered sequentially to standard doxorubicin-containing combination chemotherapy","metastatic disease":"prior therapy should have included an anthracycline unless clinically contraindicated"},"usPrevalence":null,"globalPrevalence":160000000,"prevalenceMethod":"curated","prevalenceSource":"Expert Rev Clin Pharmacol, 2019 (PMID:31287333)"},{"name":"Carcinoma of fallopian tube","source":"DrugCentral","snomedId":276870001,"regulator":"FDA","eligibility":{"advanced carcinoma":"no specific eligibility criteria mentioned"}},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"}},{"name":"Kaposi's sarcoma","source":"DrugCentral","snomedId":109385007,"regulator":"FDA","eligibility":{"second-line treatment":"AIDS-related"}},{"name":"Malignant tumor of cervix","source":"DrugCentral","snomedId":363354003,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"}},{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA","eligibility":{"advanced carcinoma":"no specific eligibility criteria mentioned"}},{"name":"Malignant tumor of peritoneum","source":"DrugCentral","snomedId":363492001,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"}},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"prior therapy":"prior therapy should have included an anthracycline unless clinically contraindicated"}},{"name":"Non-small cell lung cancer","source":"DrugCentral","snomedId":254637007,"regulator":"FDA","eligibility":{"first-line treatment":"not candidates for potentially curative surgery and/or radiation therapy"},"usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Ocular hypertension","source":"DrugCentral","snomedId":4210003,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"},"usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Open-angle glaucoma","source":"DrugCentral","snomedId":84494001,"regulator":"FDA"},{"name":"Secondary malignant neoplasm of pancreas","source":"DrugCentral","snomedId":94459006,"regulator":"FDA"}],"offLabel":[{"name":"Aphakic glaucoma","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Endometrial carcinoma","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":5,"evidenceLevel":"emerging"},{"name":"Malignant glaucoma","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Malignant tumor of head and/or neck","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":510913,"evidenceLevel":"strong"},{"name":"Malignant tumor of testis","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Malignant tumor of urinary bladder","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":14,"evidenceLevel":"moderate"},{"name":"Neoplasm of esophagus","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":46,"evidenceLevel":"moderate"},{"name":"Secondary glaucoma","source":"DrugCentral","drugName":"Nabpaclitaxel","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Small cell carcinoma of lung","source":"DrugCentral","drugName":"Nabpaclitaxel"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"docetaxel","brandName":"docetaxel","genericName":"docetaxel","approvalYear":"1996","relationship":"same-class"},{"drugId":"cabazitaxel","brandName":"cabazitaxel","genericName":"cabazitaxel","approvalYear":"2010","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":["Lung Cancer","Advanced or Metastatic Non-Small-Cell Lung Cancer","Resectable Non-Small-Cell Lung Cancer"],"enrollment":270,"completionDate":"2029-09"},{"nctId":"NCT07044453","phase":"PHASE2,PHASE3","title":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-12-08","conditions":["Resected Pancreatic Adenocarcinoma"],"enrollment":390,"completionDate":"2032-09"},{"nctId":"NCT07377045","phase":"PHASE1","title":"Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Oncomatryx Biopharma S.L.","startDate":"2025-10-28","conditions":["Pancreatic Adenocarcinoma Metastatic"],"enrollment":69,"completionDate":"2029-03"},{"nctId":"NCT05027568","phase":"PHASE1","title":"A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers","status":"COMPLETED","sponsor":"iOnctura","startDate":"2021-06-28","conditions":["Healthy"],"enrollment":40,"completionDate":"2021-09-07"},{"nctId":"NCT06037980","phase":"PHASE2,PHASE3","title":"CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-11-07","conditions":["Biliary Tract Cancer","Cholangiocarcinoma"],"enrollment":300,"completionDate":"2029-01"},{"nctId":"NCT03517176","phase":"PHASE1","title":"CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Lisata Therapeutics, Inc.","startDate":"2018-07-31","conditions":["Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":30,"completionDate":"2020-06-19"},{"nctId":"NCT06391892","phase":"PHASE3","title":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","status":"RECRUITING","sponsor":"Elisabethinen Hospital","startDate":"2024-01-11","conditions":["Pancreatic Cancer","Circulating Tumor Cell","Predictive Cancer Model"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT05371223","phase":"PHASE2","title":"Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-03-01","conditions":["Peritoneal Carcinomatosis","Pancreas Neoplasm"],"enrollment":38,"completionDate":"2025-07-30"},{"nctId":"NCT05621434","phase":"PHASE2","title":"A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2022-12-10","conditions":["HER2-positive Recurrent/Metastatic Breast Cancer"],"enrollment":63,"completionDate":"2025-12-10"},{"nctId":"NCT02117817","phase":"PHASE1","title":"Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02","conditions":["Ovarian Cancer","Endometrial Cancer","Recurrent Ovarian Cancer","Recurrent Endometrial Cancer"],"enrollment":0,"completionDate":"2015-02-25"},{"nctId":"NCT02810418","phase":"PHASE1,PHASE2","title":"Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-08-03","conditions":["Neoplasms","Pancreatic Neoplasms"],"enrollment":40,"completionDate":"2021-06-22"},{"nctId":"NCT01757288","phase":"PHASE1,PHASE2","title":"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-03-25","conditions":["STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER"],"enrollment":98,"completionDate":"2019-06-03"},{"nctId":"NCT01690702","phase":"PHASE3","title":"Study of Nab-Paclitaxel in High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-09","conditions":["Breast Cancer"],"enrollment":2886,"completionDate":"2020-07-20"},{"nctId":"NCT00709761","phase":"PHASE2","title":"Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07-02","conditions":["Neoplasms, Breast"],"enrollment":60,"completionDate":"2018-01-03"},{"nctId":"NCT03620461","phase":"","title":"Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2013-12-01","conditions":["Metastatic Pancreatic Cancer"],"enrollment":210,"completionDate":"2015-06-30"},{"nctId":"NCT03219762","phase":"PHASE2","title":"Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2017-02-07","conditions":["Small Cell Lung Cancer"],"enrollment":65,"completionDate":"2019-01"}],"_emaApprovals":[{"date":"2019-05-10","status":"Authorised","company":"TEVA BV"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"ABRAXANE"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"PACLITAXELPACLITAXEL"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Paclitaxel"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148314","MMSL":"2296","NDDF":"004116","UNII":"P88XT4IS4D","VUID":"4020736","CHEBI":"CHEBI:45863","VANDF":"4020736","INN_ID":"7052","RXNORM":"196466","UMLSCUI":"C0144576","ChEMBL_ID":"CHEMBL428647","KEGG_DRUG":"D00491","DRUGBANK_ID":"DB01229","PDB_CHEM_ID":" TA1","PUBCHEM_CID":"36314","SNOMEDCT_US":"387374002","IUPHAR_LIGAND_ID":"2770","MESH_DESCRIPTOR_UI":"D017239"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1992-","companyName":"Hq Spclt Pharma","relationship":"Original Developer"},{"period":"2019","companyName":"Teva Bv","relationship":"EMA Licensee"},{"period":"2019","companyName":"Taiho Pharmaceutical Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"11.0 hours","clearance":"6.4 mL/min/kg","bioavailability":"6%","fractionUnbound":"0.12%","volumeOfDistribution":"3.0 L/kg"},"publicationCount":2662,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:02.229477+00","atcClassification":{"source":"DrugCentral","atcCode":"L01CD01","allCodes":["L01CD01","L01CD51"]},"biosimilarFilings":[],"originalDeveloper":"Hq Spclt Pharma","recentPublications":[{"date":"2026 Mar 16","pmid":"41899178","title":"Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.","journal":"Journal of clinical medicine"},{"date":"2026 Mar 27","pmid":"41896491","title":"Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.","journal":"Journal of cancer research and clinical oncology"},{"date":"2026 Mar 17","pmid":"41892321","title":"Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.","journal":"Cells"},{"date":"2026","pmid":"41883967","title":"Case Report: Management challenges of active tuberculosis complicated by thrombocytosis and squamous cell lung carcinoma.","journal":"Frontiers in oncology"},{"date":"2026","pmid":"41883866","title":"Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.","journal":"Therapeutic advances in medical oncology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1992","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-12-29T00:00:00.000Z","mah":"HQ SPCLT PHARMA","brand_name_local":"TAXOL","application_number":"NDA020262"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2019-05-10T00:00:00.000Z","mah":"TEVA BV","brand_name_local":"Taxol","application_number":""}],"patentsNormalised":[{"patent_number":"8314156","territory":"US","patent_type":null,"expiry_date":"2023-12-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8138229","territory":"US","patent_type":null,"expiry_date":"2023-12-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7923536","territory":"US","patent_type":null,"expiry_date":"2023-12-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7923536*PED","territory":"US","patent_type":null,"expiry_date":"2024-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8314156*PED","territory":"US","patent_type":null,"expiry_date":"2024-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8138229*PED","territory":"US","patent_type":null,"expiry_date":"2024-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7820788","territory":"US","patent_type":null,"expiry_date":"2024-10-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7820788*PED","territory":"US","patent_type":null,"expiry_date":"2025-04-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7758891","territory":"US","patent_type":null,"expiry_date":"2026-02-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8268348","territory":"US","patent_type":null,"expiry_date":"2026-02-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9101543","territory":"US","patent_type":null,"expiry_date":"2026-02-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8034375","territory":"US","patent_type":null,"expiry_date":"2026-08-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8268348*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7758891*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9101543*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8034375*PED","territory":"US","patent_type":null,"expiry_date":"2027-02-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9597409","territory":"US","patent_type":null,"expiry_date":"2032-03-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9393318","territory":"US","patent_type":null,"expiry_date":"2032-03-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9597409*PED","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9393318*PED","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9511046","territory":"US","patent_type":null,"expiry_date":"2034-01-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9511046*PED","territory":"US","patent_type":null,"expiry_date":"2034-07-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}